ADHD medication shortage: 71.5% of patients cannot reliably fill prescriptions due to DEA production quotas lagging behind diagnosed demand

Among individuals prescribed ADHD medications in the past year, 71.5% reported challenges filling their prescriptions, with 38% of adults with ADHD specifically unable to find and fill their medication at any pharmacy. The shortage, ongoing since October 2022, stems from a mismatch between the DEA's annual production quota (APQ) system and actual patient demand. So what: patients who have been stable on stimulant medication for years suddenly cannot fill their prescriptions, leading to acute withdrawal of a medication that manages a neurological condition. So what: without medication, adults with ADHD lose the ability to function at work, manage finances, and maintain relationships, while children fall behind in school during critical academic years. So what: the shortage has spawned a black market and counterfeit pill ecosystem, with fentanyl-laced counterfeit Adderall causing overdose deaths. So what: the DEA increased the dextroamphetamine quota by 18%, but only 25% of that increase is allocated for domestic use, yielding just a 6.5% actual supply increase for US patients. So what: the structural mismatch between who controls supply (DEA, a law enforcement agency) and who determines medical need (physicians) means production decisions are driven by drug-war concerns rather than patient care. The structural root cause is that the Controlled Substances Act gives the DEA unilateral authority to set manufacturing quotas for Schedule II substances based on abuse-prevention goals, with no statutory requirement to ensure quotas meet legitimate medical demand, and no mechanism for patients or physicians to challenge quota decisions.